Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.

PLoS One · 2016 · PMC4723090 · PMID 26800029

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

A priori, we postulated that as an overall trend cost-effectiveness would tend to be more favorable in the early phase of the adjuvant setting than in the late phase of metastatic treatment.

also in 3,038 other papers

a possible trendno p-value reported

The aim of this study is to identify a possible trend in the cost-effectiveness for the early/adjuvant and late/metastatic stages of oncological drugs through review and case study.

also in 948 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.